Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8IV36
UPID:
HID1_HUMAN
Alternative names:
Down-regulated in multiple cancers 1; HID1 domain-containing protein; Protein hid-1 homolog
Alternative UPACC:
Q8IV36; Q8N5L6; Q8TE83; Q9NT34
Background:
Protein HID1, also known as Down-regulated in multiple cancers 1 and HID1 domain-containing protein, plays a crucial role in the development of various cancers. Its involvement in cancer biology highlights its significance in cellular processes.
Therapeutic significance:
Understanding the role of Protein HID1 could open doors to potential therapeutic strategies, especially considering its link to Developmental and epileptic encephalopathy 105 with hypopituitarism. Targeting this protein may offer new avenues for treating this debilitating condition.